Important Notice for Sage Therapeutics Investors
The Gross Law Firm is reaching out to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE), highlighting a significant class action lawsuit that requires their attention.
Class Period and Shareholder Engagement
Shareholders who purchased shares of SAGE during the designated class period are encouraged to connect with the legal team about the potential for lead plaintiff appointment. It's important to note that participating as a lead plaintiff is not a requirement for financial recovery.
Contacting the Firm
Shareholders interested in joining the lawsuit are invited to contact the law firm directly. This enables them to stay informed about the ongoing developments in their case.
Details of the Class Action
CLASS PERIOD: The time frame spans from April 12, 2021, to July 23, 2024.
ALLEGATIONS: The lawsuit alleges that during this period, the issuing of misleading statements regarding Sage's products has affected investor decisions. Specific allegations include:
- Zuranolone was purportedly less effective in treating Major Depressive Disorder than communicated to investors.
- The FDA's likelihood of approving the Zuranolone NDA in its current form was overstated.
- SAGE-718's effectiveness in treating Mild Cognitive Impairment related to Parkinson’s Disease was inaccurately presented.
- Claims regarding SAGE-324's effectiveness as a treatment for essential tremor were misleading.
As a result of these alleged misrepresentations, investors faced significant concerns and uncertainties regarding SAGE's operational and financial health.
Critical Deadlines for Participation
DEADLINE: The last date for shareholders to register their interest in participating in the class action is October 28, 2024. Immediate registration is advised to ensure eligibility.
Next Steps for Interested Shareholders
When a shareholder registers their investment made during the specified time frame, they'll gain access to portfolio monitoring tools that will keep them updated about the progression of their case. Additionally, there is no fee for participating in this lawsuit, making it accessible for all eligible investors.
About The Gross Law Firm
The Gross Law Firm is well-recognized in the field of class action litigation, striving to safeguard the rights of investors affected by unethical practices and misinformation. Their commitment is to uphold accountability among corporations, ensuring they engage in responsible business practices that contribute positively to shareholder trust and the broader community.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the importance of the upcoming deadline?
The deadline of October 28, 2024, is critical for shareholders to register their interest and potentially participate in the class action lawsuit.
Who can join the class action lawsuit?
Any shareholder who purchased shares of Sage Therapeutics Inc. during the class period (April 12, 2021, to July 23, 2024) can register to participate.
What are the allegations against Sage Therapeutics?
The allegations include misleading claims regarding the effectiveness and regulatory approval chances of SAGE products, significantly Zuranolone, SAGE-718, and SAGE-324.
Is there a cost to participate in the lawsuit?
No, there is no cost or obligation to participate in the class action for eligible shareholders.
How will I be informed about the case's status?
Registered shareholders will receive updates through a portfolio monitoring service provided by the Gross Law Firm.
